- Home
- ACRS vs VEEA Comparison
ACRS vs VEEA Comparison
Compare ACRS & VEEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- VEEA
- Stock Information
- Founded
- ACRS 2012
- VEEA 2014
- Country
- ACRS United States
- VEEA United States
- Employees
- ACRS N/A
- VEEA N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- VEEA
- Sector
- ACRS Health Care
- VEEA
- Exchange
- ACRS Nasdaq
- VEEA NYSE
- Market Cap
- ACRS 127.6M
- VEEA 112.2M
- IPO Year
- ACRS 2015
- VEEA N/A
- Fundamental
- Price
- ACRS $1.14
- VEEA $1.63
- Analyst Decision
- ACRS Strong Buy
- VEEA
- Analyst Count
- ACRS 7
- VEEA 0
- Target Price
- ACRS $11.67
- VEEA N/A
- AVG Volume (30 Days)
- ACRS 968.2K
- VEEA 13.8K
- Earning Date
- ACRS 05-06-2025
- VEEA 05-23-2025
- Dividend Yield
- ACRS N/A
- VEEA N/A
- EPS Growth
- ACRS N/A
- VEEA N/A
- EPS
- ACRS N/A
- VEEA N/A
- Revenue
- ACRS $18,720,000.00
- VEEA $141,760.00
- Revenue This Year
- ACRS N/A
- VEEA N/A
- Revenue Next Year
- ACRS $425.96
- VEEA N/A
- P/E Ratio
- ACRS N/A
- VEEA N/A
- Revenue Growth
- ACRS N/A
- VEEA N/A
- 52 Week Low
- ACRS $0.95
- VEEA $1.33
- 52 Week High
- ACRS $5.17
- VEEA $18.56
- Technical
- Relative Strength Index (RSI)
- ACRS 27.21
- VEEA N/A
- Support Level
- ACRS $1.05
- VEEA N/A
- Resistance Level
- ACRS $1.23
- VEEA N/A
- Average True Range (ATR)
- ACRS 0.11
- VEEA 0.00
- MACD
- ACRS -0.01
- VEEA 0.00
- Stochastic Oscillator
- ACRS 16.82
- VEEA 0.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About VEEA VEEA INC
Veea Inc is a company providing edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. It has first-in-class VeeaHub smart computing hubs integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.